Spinal Disc Degeneration Breakthrough: Can Scientists Reverse the Aging of Spinal Discs?

University of Utah researchers have identified a protein that may help protect spinal discs from cellular aging. The discovery is exciting, but what does it mean for people whose discs have already degenerated?
By Deborah Westergaard, M.D.
Double Board-Certified in Anesthesiology and Pain Medicine
Medical Director, Regen Experts | Dallas and Plano, Texas
November 19, 2026
Every so often, a scientific discovery makes me stop and think about where medicine may be heading.
This is one of those discoveries.
This spinal disc degeneration breakthrough was observed in laboratory studies. Whether it can help a person regain lost disc height or relieve back pain remains unknown.
Every so often, a scientific discovery makes me stop and think about where medicine may be heading.
This is one of those discoveries.
Researchers at the University of Utah have identified the function of a little-known protein called ZNF865, also known as BLST, that appears to play an important role in protecting spinal disc cells from DNA damage and cellular aging.
Even more interesting, the researchers found that increasing this protein's activity in degenerative human disc cells could reverse certain cellular changes associated with aging.
The findings were published in Aging Cell in October 2026 and highlighted by the University of Utah on November 18.
I find this enormously encouraging.
But after decades of treating patients with degenerative spinal conditions, I also have a question:
What happens when we can improve the biology of a spinal disc, but the structure of the spine has already changed?
That is where this discovery becomes particularly interesting.
What Is the New Spinal Disc Degeneration Breakthrough?
Researchers led by Robby D. Bowles, Ph.D., at the University of Utah investigated a protein called ZNF865, or BLST.
They found that this protein is present at lower levels in older and more degenerated spinal discs.
Using CRISPR-based gene regulation, they were able to increase or decrease the expression of ZNF865 in experimental models.
Three findings stood out.
First, BLST appears to help protect disc cells.
When researchers reduced its activity in healthy disc cells, they observed increased DNA damage and cellular senescence.
Cellular senescence is a condition in which cells undergo lasting changes in their normal function and can release inflammatory substances that affect surrounding tissue.
Second, increasing BLST activity improved certain characteristics of degenerative disc cells.
In human disc cells studied in the laboratory, increasing ZNF865 expression reduced DNA damage, decreased markers of senescence, and improved aspects of extracellular matrix production.
Some cellular characteristics moved toward those observed in healthier cells.
Third, reducing BLST activity in animal models produced disc degeneration and pain- related behaviors.
Together, these findings suggest that BLST may be involved in maintaining disc-cell health and could become a target for future biological therapies.
This is important research.
But it is preclinical research. Scientists have not yet demonstrated that increasing BLST can restore a degenerated human disc, prevent future disc collapse, or relieve back pain in patients.
That distinction matters.
Could CRISPR Eventually Prevent Spinal Disc Degeneration?
Potentially. That is one of the most encouraging implications of this discovery.
If researchers can identify biological mechanisms responsible for cellular aging, they may eventually develop treatments that intervene before substantial structural degeneration occurs.
Imagine a patient in their 30s or 40s whose MRI shows early disc degeneration but relatively preserved disc height.
What if we could influence the biological processes that cause disc cells to deteriorate?
Could we slow the progression of degeneration before the disc loses much of its ability to function normally?
Perhaps.
We do not yet know whether BLST-based therapies can accomplish this in humans. Nor do we know the long-term consequences of modifying a protein involved in DNA repair and cellular regulation.
Safety will be an important part of future research.
Nevertheless, the possibility is remarkable.
For younger adults, and potentially older adults with relatively preserved spinal anatomy, the long-term implications could be substantial.
I would emphasize that the biological stage of degeneration may ultimately matter more than the patient's chronological age.
A healthy 65-year-old with early disc degeneration may have a very different spinal problem from a 35-year-old with severe disc collapse.
Can This Discovery Reverse an Already Degenerated Spinal Disc?
This is where I become more cautious.
Reversing cellular aging is not the same as reversing the structural consequences of degenerative disc disease.
A spinal disc is not an isolated structure.
It is part of a complex mechanical system that includes two adjacent vertebrae, facet joints, ligaments, muscles, and neural structures.
As a disc degenerates, it may lose water, proteoglycan content, and eventually height.
When that happens, the relationship between the vertebrae changes.
And the surrounding anatomy begins to respond.
What Happens When a Spinal Disc Loses Height?
Consider a lumbar disc that has lost more than 50% of its original height.
The vertebrae are now closer together.
The facet joints behind the disc may experience altered loading and develop degenerative changes.
The neural foramina, the openings through which spinal nerves exit, may become narrower.
The ligamentum flavum may buckle into the spinal canal.
Osteophytes can develop along the vertebral margins and facet joints.
Over time, the entire spinal motion segment may undergo structural remodeling.
These changes do not occur identically in every patient. Some people have substantial degeneration without significant symptoms. Others develop mechanical back pain, radicular symptoms, or neurological deficits.
But the important point is this:
Once the disc has collapsed, the problem may no longer be confined to the disc itself.
Even if scientists could make the remaining disc cells biologically healthier, that would not necessarily restore the original disc height, reverse facet arthropathy, enlarge a narrowed neural foramen, or correct every secondary mechanical change.
A biologically healthier disc does not automatically mean a mechanically restored spine.
And it certainly does not guarantee a pain-free patient.
Three Stages of Spinal Disc Degeneration

Stage 1: Preserved spinal anatomy
The disc maintains normal height, the facet joints have preserved articular relationships, and the neural foramina provide adequate space for the exiting nerve roots.
Stage 2: Developing degeneration
Disc hydration and height begin to decrease. Facet loading may change, degenerative remodeling can develop, and foraminal dimensions may begin to narrow.
Stage 3: Advanced degeneration
Substantial disc-height loss may coexist with facet hypertrophy, osteophytes, ligamentous thickening, and neural foraminal stenosis. In some patients, the exiting nerve root becomes compressed.
These illustrations show one possible progression, not the inevitable course of every degenerating disc.
This is why I believe the future of spinal preservation must address more than disc-cell biology.
What Does This Mean for Generation X and Baby Boomers?
I see many patients in midlife and later adulthood who want to remain active.
They want to travel, play golf or pickleball, exercise, hike, and enjoy the freedom that comes with maintaining their mobility.
They have also accumulated decades of spinal loading, injuries, and age-related changes.
One of the lovely things about growing older is that we acquire wisdom and experience.
Unfortunately, our spines do not always age as gracefully as our minds.
For people who already have substantial disc-height loss, advanced facet arthropathy, or foraminal stenosis, a future treatment directed at BLST alone may not address the entire problem.
That does not mean this research is irrelevant to older patients.
It may eventually have applications in earlier-stage degeneration regardless of age. We also cannot exclude the possibility that modifying disc biology could provide benefits even when some structural changes remain.
We simply do not know yet.
What I would not want patients to conclude is that a therapy capable of improving cellular aging markers has already been shown to rebuild a collapsed spinal disc.
It has not.
Could We Eventually Grow a Replacement Spinal Disc?
This is the question that interests me most.
If scientists eventually learn to protect disc cells from degeneration, what comes next?
What do we do for the patient whose disc has already lost 60% or 70% of its height?
What if the facet joints have remodeled, the neural foramina have narrowed, and the original anatomy can no longer be restored simply by improving the remaining disc cells?
Perhaps the next major challenge will be biological reconstruction.
Researchers are already investigating tissue-engineered intervertebral discs, living cells, biomaterial scaffolds, and ways to recreate the extracellular matrix that gives a disc its mechanical properties.
The concept is fascinating.
Could we eventually grow a living replacement disc using a patient's own cells?
Could we engineer a structure that resembles the patient's original disc before degeneration?
Could it integrate with the vertebral endplates, withstand normal spinal loading, and restore useful motion?
These are scientific questions, not established treatment possibilities for patients today.
A functional disc would need to reproduce the complex behavior of the nucleus pulposus, annulus fibrosus, and vertebral endplates.
It would need to survive millions of loading cycles and maintain adequate nutrient exchange.
And replacing the disc would not necessarily correct all the degenerative changes already present in the surrounding motion segment.
Perhaps future reconstruction will require us to think beyond the disc itself.
Could we eventually reconstruct an entire functional spinal motion segment using living, engineered tissue?
I do not expect that to become routine clinical medicine in the immediate future.
But I no longer consider it unreasonable to ask the question.
What Role Might Artificial Intelligence Play?
I am particularly interested in the convergence of artificial intelligence, molecular biology, advanced imaging, and tissue engineering.
AI may help researchers analyze enormous biological datasets, identify molecular targets, model tissue behavior, and design experiments more efficiently.
It may also eventually improve our ability to identify which patients have primarily biological degeneration, which have substantial mechanical disease, and which may respond to particular interventions.
That is a future possibility, not an established clinical capability.
The University of Utah study demonstrates CRISPR-based regulation of BLST. It does not establish that AI was responsible for the discovery.
Still, the broader convergence of these technologies is one reason I am optimistic about the future of musculoskeletal medicine.
We are beginning to ask questions that were difficult to investigate only a few years ago.
What Can Patients With Degenerative Disc Disease Do Today?
For patients who already have chronic back pain or degenerative disc disease, the immediate question is not whether BLST therapy will become available.
It is understanding what is causing their symptoms now.
An MRI provides important information, but it does not examine the patient.
Disc degeneration on imaging does not automatically mean the disc is responsible for the pain.
A patient may have discogenic pain, facet-mediated pain, sacroiliac joint dysfunction, nerve-root irritation, spinal stenosis, muscular dysfunction, or more than one contributing pain generator.
That distinction determines which treatments may be reasonable.
Some patients benefit from exercise-based rehabilitation, activity modification, and conservative management.
Selected patients may be candidates for image-guided diagnostic procedures or other nonoperative interventions.
Orthobiologic treatments, including platelet-rich plasma or other autologous preparations, may be considered in selected circumstances, but evidence varies by condition and technique. They are not established methods for restoring advanced disc height or reversing spinal stenosis.
And sometimes surgery is the appropriate treatment.
Progressive neurological weakness, clinically significant neural compression, instability, or other structural conditions may require surgical evaluation.
The important decision is not which procedure to perform first.
It is determining which structures are responsible for the patient's symptoms, what treatment is justified, and what the patient hopes to return to doing.
My Perspective: The Future of Spine Medicine Is Preservation, Then Reconstruction
I find the University of Utah discovery genuinely exciting.
Not because we have found a cure for degenerative disc disease.
We have not.
And not because CRISPR can currently restore a collapsed spinal disc.
There is no clinical evidence demonstrating that.
I am excited because researchers have identified a biological mechanism that may eventually allow us to influence how spinal discs age.
For patients with early degeneration, that could open important avenues of investigation.
For patients with advanced degeneration, it highlights an equally important challenge: how do we address the structural consequences that have already developed?
Perhaps the future will involve preserving healthy disc cells before degeneration progresses.
Perhaps it will involve reconstructing damaged tissue.
And perhaps, one day, we will learn to engineer a living replacement for a spinal structure that can no longer be preserved.
I have spent much of my career evaluating the consequences of spinal degeneration.
The possibility that future generations of physicians may be able to intervene earlier, before those consequences develop, gives me considerable hope.
We may be learning how to influence the aging of spinal discs. The next great challenge may be learning how to rebuild a functional spinal motion segment after degeneration has already occurred.
That is a future worth investigating.
About the Author
Deborah Westergaard, M.D., is double board-certified in Anesthesiology and Pain Medicine and Medical Director of Regen Experts in Dallas and Plano, Texas. Her practice focuses on physician-led evaluation of complex spine and joint conditions, image-guided procedures, and thoughtful consideration of nonoperative treatment options when appropriate.
Her clinical approach begins with identifying the likely source of pain and determining whether intervention is warranted.
Research Reference
Lewis C, Levis H, Holbrook J, et al. ZNF865 (BLST) a Novel Regulator of DNA Damage and Cell Senescence in Back Pain. Aging Cell. 2026;25(10):e70754.
Frequently Asked Questions
Can scientists reverse degenerative disc disease?
Scientists have reversed certain cellular markers associated with disc aging in laboratory experiments. However, no BLST-based treatment has been shown to reverse degenerative disc disease or restore spinal disc anatomy in human patients.
What is the BLST protein discovered by University of Utah researchers?
BLST, also called ZNF865, is a protein involved in regulating DNA damage, cellular senescence, and other cellular processes. University of Utah researchers found that changing its expression affected the health of spinal disc cells in preclinical experiments.
Can CRISPR restore the height of a collapsed spinal disc?
There is currently no clinical evidence that CRISPR-based BLST therapy restores disc height. Advanced disc collapse may also involve facet arthritis, osteophytes, and neural foraminal narrowing that would not necessarily resolve by improving disc-cell health.
Will this discovery help older adults with degenerative discs?
Possibly, but its clinical benefits remain unknown. The extent of structural degeneration and remaining disc integrity may eventually matter more than age alone. Patients with advanced degeneration often have additional mechanical changes requiring separate evaluation.
Can disc degeneration cause foraminal stenosis and nerve compression?
Yes. Disc-height loss can contribute to narrowing of the neural foramina. Facet hypertrophy, osteophytes, and other degenerative changes may further reduce space around the exiting nerve root. Imaging findings must be correlated with symptoms and examination.
Is BLST gene therapy available for back pain?
No. BLST-directed CRISPR treatment for degenerative disc disease remains investigational. Human clinical safety, effectiveness, delivery methods, and long-term outcomes have not been established.
Degenerative Disc Disease: Understand What Is Causing Your Pain
If you have been told that your MRI shows degenerative disc disease, spinal stenosis, or facet arthritis, the next step is determining which findings are actually contributing to your symptoms.
At Regen Experts, Dr. Deborah Westergaard evaluates spinal anatomy, imaging, examination findings, and functional goals before recommending treatment.
Some patients have reasonable nonoperative options. Others may benefit from surgical consultation.

Comments